Advertisement Sidebar
Recent Posts
- NATERA GALAXY Study Links ctDNA Status to Survival & Treatment Response ESMO 2024
- FDA approves KEYTRUDA® / Pembrolizumab with Chemotherapy for Unresectable Advanced or Metastatic Malignant Pleural Mesothelioma SLIDES
- SLIDES: FDA Approves Kisqali / Ribociclib for Early High-Risk Breast Cancer
- VIDEO: iTeos and GSK’s TIGIT Combination Therapy Shows Significant Promise at ESMO 2024
- VIDEO: FDA Approves Atezolizumab / Tecentriq Hybreza For Subcutaneous PD-(L)1 Cancer Immunotherapy in NSCLC
Oncology Conference Videos
Oncology News
In an ongoing Phase 1/2 study, Constantine Tam, MD, a researcher and Professor of Haematology,…
At ASH 2023, Katherine Broome, MD, a medical doctor and medical oncologist at the Georgetown…
Under the lights of ASH 2023, the microphone poised to capture insights, Dr. Lorenzo Falchi,…
In an interview, Andrew Evens, DO, an expert in hematology and oncology, will discuss a…
By: Hope Rugo, MD Date: 12/9/2023 At the SABCS 2023 conference, medical oncologist Hope Rugo…
Wassim Mchayleh, MD, a speaker at the Medical Data and Analysis Symposium (MDAS), discusses the…
Allen Wilbanks stands at the forefront of SABCS 2023, the setting for a conversation with…
Rabi Hanna, MD, from the Department of Pediatric Hematology Oncology and BMT at Cleveland Clinic…
Zandra Klippel, MD, Global Product Head, Sanofi – Phase 3 IsKia trial of Sarclisa® (isatuximab)…
At ASH 2023, Ola Landgren, MD, Professor of Medicine and Chief Division of Myeloma at…
Introduction to Myelofibrosis and JAK Inhibitors Myelofibrosis, a complex myeloproliferative neoplasm, presents a unique set…